Acadian Asset Management LLC Raises Stake in Thermo Fisher Scientific Inc. (NYSE:TMO)

Acadian Asset Management LLC boosted its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 3.8% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 24,580 shares of the medical research company’s stock after buying an additional 909 shares during the period. Acadian Asset Management LLC’s holdings in Thermo Fisher Scientific were worth $14,282,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently bought and sold shares of the company. Rosenberg Matthew Hamilton increased its stake in Thermo Fisher Scientific by 3.7% during the fourth quarter. Rosenberg Matthew Hamilton now owns 526 shares of the medical research company’s stock worth $279,000 after acquiring an additional 19 shares during the last quarter. Tsfg LLC increased its stake in Thermo Fisher Scientific by 8.3% during the fourth quarter. Tsfg LLC now owns 249 shares of the medical research company’s stock worth $132,000 after acquiring an additional 19 shares during the last quarter. Foundations Investment Advisors LLC increased its stake in Thermo Fisher Scientific by 1.9% during the fourth quarter. Foundations Investment Advisors LLC now owns 1,069 shares of the medical research company’s stock worth $591,000 after acquiring an additional 20 shares during the last quarter. Paragon Private Wealth Management LLC increased its stake in Thermo Fisher Scientific by 4.3% during the fourth quarter. Paragon Private Wealth Management LLC now owns 480 shares of the medical research company’s stock worth $255,000 after acquiring an additional 20 shares during the last quarter. Finally, Physician Wealth Advisors Inc. grew its stake in shares of Thermo Fisher Scientific by 3.4% in the first quarter. Physician Wealth Advisors Inc. now owns 607 shares of the medical research company’s stock valued at $337,000 after buying an additional 20 shares in the last quarter. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Insider Transactions at Thermo Fisher Scientific

In other news, SVP Michael A. Boxer sold 2,000 shares of Thermo Fisher Scientific stock in a transaction dated Friday, April 26th. The stock was sold at an average price of $567.94, for a total value of $1,135,880.00. Following the transaction, the senior vice president now directly owns 13,083 shares in the company, valued at $7,430,359.02. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, CEO Marc N. Casper sold 10,000 shares of the business’s stock in a transaction dated Monday, June 3rd. The stock was sold at an average price of $567.28, for a total transaction of $5,672,800.00. Following the transaction, the chief executive officer now directly owns 123,816 shares in the company, valued at $70,238,340.48. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Michael A. Boxer sold 2,000 shares of the business’s stock in a transaction dated Friday, April 26th. The shares were sold at an average price of $567.94, for a total value of $1,135,880.00. Following the transaction, the senior vice president now owns 13,083 shares in the company, valued at $7,430,359.02. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 22,000 shares of company stock worth $12,532,780. Company insiders own 0.34% of the company’s stock.

Thermo Fisher Scientific Stock Down 1.2 %

TMO traded down $6.27 during trading on Friday, reaching $534.35. 1,667,269 shares of the stock traded hands, compared to its average volume of 1,636,182. The stock has a market cap of $203.97 billion, a price-to-earnings ratio of 34.28, a price-to-earnings-growth ratio of 2.49 and a beta of 0.77. Thermo Fisher Scientific Inc. has a fifty-two week low of $415.60 and a fifty-two week high of $603.82. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.70 and a quick ratio of 1.33. The stock’s 50-day simple moving average is $565.05 and its two-hundred day simple moving average is $564.70.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings results on Wednesday, April 24th. The medical research company reported $5.11 earnings per share for the quarter, topping analysts’ consensus estimates of $4.70 by $0.41. Thermo Fisher Scientific had a return on equity of 18.45% and a net margin of 14.20%. The company had revenue of $10.35 billion during the quarter, compared to analysts’ expectations of $10.14 billion. As a group, equities research analysts expect that Thermo Fisher Scientific Inc. will post 21.64 EPS for the current year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, October 15th. Stockholders of record on Friday, September 13th will be paid a $0.39 dividend. The ex-dividend date is Friday, September 13th. This represents a $1.56 dividend on an annualized basis and a dividend yield of 0.29%. Thermo Fisher Scientific’s payout ratio is presently 10.01%.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on TMO. Robert W. Baird lowered their target price on Thermo Fisher Scientific from $621.00 to $620.00 and set an “outperform” rating for the company in a research note on Thursday, April 25th. Deutsche Bank Aktiengesellschaft raised their price objective on Thermo Fisher Scientific from $600.00 to $610.00 and gave the company a “buy” rating in a research note on Thursday, April 25th. HSBC raised their price target on Thermo Fisher Scientific from $660.00 to $670.00 and gave the stock a “buy” rating in a report on Tuesday, April 30th. The Goldman Sachs Group raised their target price on Thermo Fisher Scientific from $550.00 to $640.00 and gave the company a “buy” rating in a research report on Wednesday, April 10th. Finally, Barclays decreased their target price on Thermo Fisher Scientific from $615.00 to $600.00 and set an “equal weight” rating for the company in a research report on Friday, June 28th. Five equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $605.63.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.